FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy

Cancer Research

Volumn 72, Issue 19, 2012, Pages 5014-5024

  Li, Zhoulei ^a   Graf, Nicolas ^a   Herrmann, Ken ^a   Jun, Alexandra ^a   Aichler, Michaela ^b   Feuchtinger, Annette ^b   Baumgart, Anja ^a   Walch, Axel ^b   Peschel, Christian ^a   Schwaiger, Markus ^a   Buck, Andreas ^c   Keller, Ulrich ^a   Dechow, Tobias ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d Onkologie Ravensburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CASPASE 3; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; DRUG SENSITIVITY; DRUG TARGETING; DRUG UPTAKE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; XENOTRANSPLANTATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DIDEOXYNUCLEOSIDES; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-TYROSINE KINASES; RESORCINOLS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867130157     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0635     Document Type: Article

References (48)

1. Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009;23:11-23.
2. Dupire S, Coiffier B. Targeted treatment and new agents in diffuse large B cell lymphoma. Int J Hematol 2010;92:12-24.
3. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85-96.
4. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-54.
5. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)
6. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81. (Pubitemid 41129604)
7. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23. (Pubitemid 41222425)
8. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. The interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:2066-73.
9. Moskowitz CH, Zelenetz A, Schoder H. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw 2010;8:347-52.
10. Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896-903.
11. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
12. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001;42:721-5. (Pubitemid 32453459)
13. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
14. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055-61. (Pubitemid 44877006)
15. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31. (Pubitemid 39663355)
16. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-12. (Pubitemid 41541493)
17. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, et al. 3 -[18F] fluoro-3 -deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7. (Pubitemid 36605213)
18. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18 F] FLT. Eur J Nucl Med Mol Imaging 2007;34:1775-82. (Pubitemid 47599048)
19. Dittmann H, Dohmen B, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18 F] FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9. (Pubitemid 35232048)
20. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008;10:349-55.
21. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al. Early response assessment using 3′-Deoxy-3′-[F-18]fluorothymidine- positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552-8. (Pubitemid 46955115)
22. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994;9:1567-74. (Pubitemid 24163381)
23. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, Alk, to a nucleolar protein gene, Npm, in non-Hodgkins-lymphoma. Science 1994;263:1281-4. (Pubitemid 24107549)
24. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. NPM-ALK associated with anaplastic large-cell lymphoma activates the PI3-kinase/AKT antiapoptotic signaling pathway. Blood 2000;96:4319-27.
25. Chiarle R, Simmons WJ, Cai HY, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11:623-9. (Pubitemid 40868302)
26. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559-66. (Pubitemid 34407823)
27. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-97. (Pubitemid 44085614)
28. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson J. Simplified labeling approach for synthesizing 3 -deoxy-3 -[18F] fluorothymidine ([18F] FLT). J Radioanalytical Nucl Chem 2000;243:843-6. (Pubitemid 30462551)
29. Sawas A, Diefenbach C, O'Connor OA. New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol 2011;18:280-7.
30. Sweetenham JW. Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma. Curr Opin Hematol 2011;18:288-92.
31. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
32. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010;1:530-43.
33. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001;61:2194-9. (Pubitemid 32692047)
34. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-47. (Pubitemid 34174516)
35. Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia Echeverria C, et al. Synergistic action of the novel HSP90 inhibitor NVP AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Euro J Haematol 2010;84:337-44.
36. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7.
37. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20:309-18.
38. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704.
39. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006;47:793-6. (Pubitemid 46768442)
40. Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922. J Nucl Med 2008;49:1204-10. (Pubitemid 351948032)
41. Jensen MM, Erichsen KD, Bjorkling F, Madsen J, Jensen PB, Hojgaard L, et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PloS ONE 2010;5:e12965.
42. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 2009;50:1102-9.
43. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
44. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435-42. (Pubitemid 41637983)
45. Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, et al. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res 2011;17:5322-32.
46. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
47. Lane HA, Wood JM, McSheehy PMJ, Allegrini PR, Boulay A, Brueggen J, et al. mTOR Inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009;15:1612-22.
48. Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, et al. Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Trans Oncol 2010;3:264-75.